TetraLogic Research & Development

TetraLogic Research & Development Corp.TetraLogic Research & Development Corp. operates in the pharmaceutical sector, dedicated to the research and development of novel therapies. The company was acquired by TetraLogic Pharmaceuticals in April 2014 for USD 13 mn, marking a significant shift in its operational strategy.com offers a suite of services centered around the sale of digital assets, specifically domain names. Their primary focus is on facilitating the acquisition and transfer of domain names, ensuring a simple and secure transaction process for their customers. The company caters to a diverse clientele, including startups, established businesses, and individual entrepreneurs seeking to enhance their online presence.com serves global markets, providing its offerings to clients in North America, Europe, and Asia, among others. The end users of their services benefit from acquiring unique and relevant domain names that can significantly improve their branding and digital marketing efforts.com generates revenue through direct transactions involving the sale of domain names. The business model typically involves one-time purchases, with customers engaging in negotiations for specific domain names that align with their branding needs. Partnerships with online platforms or resellers may further enhance distribution and customer reach, allowing for broader access to potential buyers. The company’s pricing structure is competitive, reflecting the market value of desirable domain names.com may also provide additional services such as domain appraisal and transfer assistance, which contributes to the overall customer experience and supports their revenue stream.TetraLogic Research & Development Corp. is poised for future growth with plans to enhance its therapeutic product offerings. The recent acquisition in April 2014 by TetraLogic Pharmaceuticals is expected to facilitate the development of new therapies targeting unmet medical needs. The company aims to expand its reach into emerging markets, with a focus on specific regions in Europe and Asia by 2025.

1. Series B

   Oct 1, 2010

   Amount

   $1M

   Investors

   Locked